Lilly Wants Judge To Schedule June Arguments in 340B Suit Against HHS

Drug maker Eli Lilly's motion yesterday in its 340B contract pharmacy lawsuit against HHS mainly covered the same ground as in its original January complaint. | Shutterstock
Drug manufacturer Eli Lilly yesterday asked a federal district judge in Indianapolis to schedule oral argument as soon as mid-June in its lawsuit challenging both a federal legal advisory opinion about 340B contract pharmacy and the 340B program’s new administrative
Read More »

Multiple Developments in AstraZeneca’s 340B Contract Pharmacy Lawsuit

There were a handful of significant developments this week AstraZeneca's lawsuit to derail an HHS advisory opinion on 340B contract pharmacy.
The plain language of the 340B statute “explicitly requires drug manufacturers to offer 340B discounts to 340B covered entities regardless of whether the drugs are dispensed by the entity or by an outside pharmacy with which the entity has a
Read More »

State Attorney General Is Investigating Lilly and AstraZeneca’s 340B Pricing

Eli Lilly and AstraZeneca are the latest drug makers to disclose that they have been subpoenaed by Vermont's top law enforcement official for documents and information about their participation in 340B. | Shutterstock
Eli Lilly and AstraZeneca are the latest drug makers to disclose they have received a subpoena from the Vermont attorney general’s office related to their denials of 340B ceiling prices on drugs shipped to contract pharmacies.
Read More »

Vermont AG Issues Subpoena to Novartis for 340B Documents and Information

Novartis is the second known drug manufacturer subpoenaed by the Vermont attorney general over manufacturer denials of or restrictions on 340B pricing for drugs shipped to contract pharmacies.

Vermont’s top law enforcement official has asked a second drug manufacturer—Novartis—for documents and information concerning the company’s participation in the 340B program in the state.

Tuesday in its interim financial report for the first quarter of 2021, the Swiss

Read More »

Hospitals Could Get Another Shot to Intervene in AstraZeneca’s 340B Lawsuit

A federal judge in Delaware yesterday left the door open to letting hospital groups participate as third parties in a drugmaker’s lawsuit challenging the federal government’s 340B program contract pharmacy enforcement mechanisms. | Shutterstock
A federal judge in Delaware yesterday declined to add hospital groups as third parties to a drugmaker’s lawsuit challenging the federal government’s 340B program contract pharmacy guidelines. But he left the door open to letting the groups participate as litigants
Read More »

BREAKING: Judge Nixes Hospital Groups’ Participation in AstraZeneca’s 340B Contract Pharmacy Case

Six hospital groups cannot participate as third parties in drug manufacturer AstraZeneca’s lawsuit against the government over its 340B contract pharmacy requirements, a judge ruled this morning in federal district court in Wilmington, Del. (pictured).
A federal district judge in Wilmington, Del., ruled this morning that six hospital groups cannot participate as third parties in drug manufacturer AstraZeneca’s lawsuit against the government over its 340B contract pharmacy requirements.

Please Login or

Read More »

Feds Asks Courts to Reject Lilly and Sanofi’s 340B “Self-Help”

Lawyers for HHS have asked federal courts in Indianapolis (above) and New Jersey to dismiss 340B-related lawsuits against the department brought by drugmakers Eli Lilly and Sanofi.
U.S. Justice Department (DOJ) lawyers asked federal district courts in Indiana and New Jersey this week to condemn, not condone, drugmakers Eli Lilly and Sanofi’s “extra-statutory self-help efforts to rewrite” the 340B statute “under the guise of ‘program integrity’” and
Read More »

AstraZeneca Tells Court: Congress Didn’t Make 340B to Generate Profits for Providers

A federal district judge is considering AstraZeneca’s emergency motion yesterday for a stay in its lawsuit over the government’s efforts to compel it to resume 340B pricing on drugs dispensed by contract pharmacies.
Congress never intended for safety-net health care providers to make money by buying prescriptions drugs at a discount through the 340B program and billing payers at above the drugs’ acquisition cost, drug manufacturer AstraZeneca (AZN) told a federal district court
Read More »

340B Entities Won’t Share in BMS’s $75 Million Medicaid Drug Pricing Settlement

A whistleblower alleged that Bristol-Myers Squibb misreported prices on more than 200 drug products, reducing Medicaid rebates it owed to states.
340B covered entities were not included in Bristol-Myers Squibb’s $75 million settlement last week of a whistleblower’s claims that BMS “falsely reported improperly reduced average manufacturer prices” (AMPs) on multiple drugs from October 2007 through March 2016.
Read More »